ThirtyFiveBio is an Oxford, UK biotechnology company founded in 2021 to develop first-in-class small-molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal diseases, including ulcerative colitis, inflammatory bowel disease, and digestive-tract cancers. - View it on GitHub